Current and historical daily PE Ratio for SynAct Pharma AB (
OSTO:SYNACT
) from 2016 to Jun 17 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. SynAct Pharma AB stock (OSTO:SYNACT) PE ratio as of Jun 17 2024 is 0.
More Details
SynAct Pharma AB (OSTO:SYNACT) PE Ratio (TTM) Chart
SynAct Pharma AB (OSTO:SYNACT) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1273
- 1
- 2
- 3
- 4
- 5
- 6
- 15
SynAct Pharma AB PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-17 | At Loss | 2024-04-10 | At Loss |
2024-06-14 | At Loss | 2024-04-09 | At Loss |
2024-06-13 | At Loss | 2024-04-08 | At Loss |
2024-06-12 | At Loss | 2024-04-05 | At Loss |
2024-06-11 | At Loss | 2024-04-04 | At Loss |
2024-06-10 | At Loss | 2024-04-03 | At Loss |
2024-06-07 | At Loss | 2024-04-02 | At Loss |
2024-06-05 | At Loss | 2024-03-28 | At Loss |
2024-06-04 | At Loss | 2024-03-27 | At Loss |
2024-06-03 | At Loss | 2024-03-26 | At Loss |
2024-05-31 | At Loss | 2024-03-25 | At Loss |
2024-05-30 | At Loss | 2024-03-22 | At Loss |
2024-05-29 | At Loss | 2024-03-21 | At Loss |
2024-05-28 | At Loss | 2024-03-20 | At Loss |
2024-05-27 | At Loss | 2024-03-19 | At Loss |
2024-05-24 | At Loss | 2024-03-18 | At Loss |
2024-05-23 | At Loss | 2024-03-15 | At Loss |
2024-05-22 | At Loss | 2024-03-14 | At Loss |
2024-05-21 | At Loss | 2024-03-13 | At Loss |
2024-05-20 | At Loss | 2024-03-12 | At Loss |
2024-05-17 | At Loss | 2024-03-11 | At Loss |
2024-05-16 | At Loss | 2024-03-08 | At Loss |
2024-05-15 | At Loss | 2024-03-07 | At Loss |
2024-05-14 | At Loss | 2024-03-06 | At Loss |
2024-05-13 | At Loss | 2024-03-05 | At Loss |
2024-05-10 | At Loss | 2024-03-04 | At Loss |
2024-05-08 | At Loss | 2024-03-01 | At Loss |
2024-05-07 | At Loss | 2024-02-29 | At Loss |
2024-05-06 | At Loss | 2024-02-28 | At Loss |
2024-05-03 | At Loss | 2024-02-27 | At Loss |
2024-05-02 | At Loss | 2024-02-26 | At Loss |
2024-04-30 | At Loss | 2024-02-23 | At Loss |
2024-04-29 | At Loss | 2024-02-22 | At Loss |
2024-04-26 | At Loss | 2024-02-21 | At Loss |
2024-04-25 | At Loss | 2024-02-20 | At Loss |
2024-04-24 | At Loss | 2024-02-19 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
2024-04-18 | At Loss | 2024-02-13 | At Loss |
2024-04-17 | At Loss | 2024-02-12 | At Loss |
2024-04-16 | At Loss | 2024-02-09 | At Loss |
2024-04-15 | At Loss | 2024-02-08 | At Loss |
2024-04-12 | At Loss | 2024-02-07 | At Loss |
2024-04-11 | At Loss | 2024-02-06 | At Loss |
SynAct Pharma AB (OSTO:SYNACT) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
SynAct Pharma AB
ISIN : SE0008241491
Compare
Compare
Traded in other countries / regions
SYNACT.Sweden8F8.Germany IPO Date
2016-07-11Description
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.